Table 1.

 Inhibitory effect on HepG2 cell proliferation by bufalin and cinobufagin

Reagents (μmol/L)	Cell viability (%)
	24 h	48 h	72 h
Bufalin
0	100.00	100.00	100.00
10−4	91.99 ± 0.68*	85.61 ± 2.07***	82.43 ± 0.85***
10−3	84.11 ± 4.24***	79.32 ± 3.66***	74.22 ± 1.34***
10−2	76.02 ± 4.32***	72.74 ± 2.82***	67.44 ± 1.79***
10−1	63.14 ± 2.75***	61.72 ± 1.71***	48.89 ± 1.02***
1	41.61 ± 2.31***	37.30 ± 3.62***	26.35 ± 0.88***
10	33.51 ± 2.05***	29.70 ± 2.55***	19.56 ± 0.98***
100	25.16 ± 0.74***	25.21 ± 0.60***	14.69 ± 0.95***
Cinobufagin
0	100.00	100.00	100.00
10−4	92.91 ± 3.29*	91.61 ± 0.42***	90.86 ± 1.89**
10−3	88.54 ± 5.26**	81.95 ± 2.37***	71.21 ± 2.33***
10−2	78.77 ± 5.98***	73.02 ± 0.17***	63.71 ± 3.01***
10−1	67.68 ± 4.33***	62.21 ± 2.45***	57.83 ± 5.00***
1	49.36 ± 1.64***	42.20 ± 2.20***	40.20 ± 2.30***
10	35.14 ± 4.64***	25.63 ± 1.21***	26.52 ± 2.43***
100	23.50 ± 2.72***	22.30 ± 0.75***	15.07 ± 1.66***

Data are shown as mean ± SD (n = 3). *P < 0.05, **P < 0.01 and ***P < 0.001 versus untreated controls.